Pathophysiology of COVID-19-Related Extrapyramidal Disorders.
Atypical parkinsonism
COVID‐19
Extrapyramidal
Parkinsonism
Parkinson’s disease
Pathophysiology
SARS-CoV-2
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2024
2024
Historique:
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
16
9
2024
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) has been associated with a variety of neurological manifestations (i.e., anosmia, ageusia, myalgia, headache) and neurological syndromes (i.e., encephalopathy, ischemic and hemorrhagic stroke, myelitis, encephalitis) underlying different pathogenetic mechanisms. COVID-19 has also been associated with various movement disorders including acute or subacute parkinsonism. However, to date, only few cases of parkinsonism linked to COVID-19 have been reported, nevertheless raising the possibility of a post-viral parkinsonian syndrome. Furthermore, various studies in vitro and in animal models have highlighted a close relationship between SARS-CoV-2 virus and α-synuclein, leading to the hypothesis that COVID-19 could represent a factor favoring the long-term development of α-synucleopathies. In this chapter, we will discuss the pathophysiological mechanisms related to movement disorders' manifestations of COVID-19 focusing on the possible overlap between pathogenetic mechanisms of Parkinson's Disease and COVID-19.
Identifiants
pubmed: 39283423
doi: 10.1007/978-3-031-61939-7_6
doi:
Substances chimiques
alpha-Synuclein
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
111-123Informations de copyright
© 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Alam MS, Czajkowsky DM (2022) SARS-CoV-2 infection and oxidative stress: pathophysiological insight into thrombosis and therapeutic opportunities. Cytokine Growth Factor Rev 63:44–57. https://doi.org/10.1016/j.cytogfr.2021.11.001
doi: 10.1016/j.cytogfr.2021.11.001
pubmed: 34836751
Albornoz EA, Amarilla AA, Modhiran N et al (2022) SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein. Mol Psychiatry. https://doi.org/10.1038/s41380-022-01831-0
doi: 10.1038/s41380-022-01831-0
pubmed: 36316366
pmcid: 10615762
Awogbindin IO, Ben-Azu B, Olusola BA et al (2021) Microglial Implications in SARS-CoV-2 Infection and COVID-19: lessons from viral RNA neurotropism and possible relevance to Parkinson’s disease. Front Cell Neurosci 15:670298. https://doi.org/10.3389/fncel.2021.670298
doi: 10.3389/fncel.2021.670298
pubmed: 34211370
pmcid: 8240959
Beauchamp LC, Finkelstein DI, Bush AI et al (2020) Parkinsonism as a third wave of the COVID-19 pandemic? J Parkinsons Dis 10:1343–1353. https://doi.org/10.3233/JPD-202211
doi: 10.3233/JPD-202211
pubmed: 32986683
pmcid: 7683045
Beckman D, Bonillas A, Diniz GB et al (2022) SARS-CoV-2 infects neurons and induces neuroinflammation in a non-human primate model of COVID-19. Cell Rep 41:111573. https://doi.org/10.1016/j.celrep.2022.111573
doi: 10.1016/j.celrep.2022.111573
pubmed: 36288725
pmcid: 9554328
Beghi E, Helbok R, Crean M et al (2021) The European Academy of Neurology COVID-19 registry (ENERGY): an international instrument for surveillance of neurological complications in patients with COVID-19. Eur J Neurol 28:3303–3323. https://doi.org/10.1111/ene.14652
doi: 10.1111/ene.14652
pubmed: 33220127
Beghi E, Moro E, Davidescu EI et al (2023) Comparative features and outcomes of major neurological complications of COVID-19. Euro J Neurol 30:413–433. https://doi.org/10.1111/ene.15617
Bentea E, Verbruggen L, Massie A (2017) The Proteasome inhibition model of Parkinson’s disease. J Parkinsons Dis 7:31–63. https://doi.org/10.3233/JPD-160921
doi: 10.3233/JPD-160921
pubmed: 27802243
pmcid: 5302045
Bhowal C, Ghosh S, Ghatak D, De R (2022) Pathophysiological involvement of host mitochondria in SARS-CoV-2 infection that causes COVID-19: a comprehensive evidential insight. Mol Cell Biochem. https://doi.org/10.1007/s11010-022-04593-z
doi: 10.1007/s11010-022-04593-z
pubmed: 36308668
pmcid: 9617539
Blanco-Palmero VA, Azcárate-Díaz FJ, Ruiz-Ortiz M et al (2021) Serum and CSF alpha-synuclein levels do not change in COVID-19 patients with neurological symptoms. J Neurol 268:3116–3124. https://doi.org/10.1007/s00415-021-10444-6
doi: 10.1007/s00415-021-10444-6
pubmed: 33606070
pmcid: 7892700
Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR (2015) Oxidative stress and Parkinson’s disease. Front Neuroanat 9. https://doi.org/10.3389/fnana.2015.00091
Bodro M, Compta Y, Sánchez-Valle R (2021) Presentations and mechanisms of CNS disorders related to COVID-19. Neurol Neuroimmunol Neuroinflamm 8:e923. https://doi.org/10.1212/NXI.0000000000000923
doi: 10.1212/NXI.0000000000000923
pubmed: 33310765
Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM (2018) Neurologic alterations due to respiratory virus infections. Front Cell Neurosci 12:386. https://doi.org/10.3389/fncel.2018.00386
doi: 10.3389/fncel.2018.00386
pubmed: 30416428
pmcid: 6212673
Borsche M, Pereira SL, Klein C, Grünewald A (2021) Mitochondria and Parkinson’s disease: clinical, molecular, and translational aspects. J Parkinsons Dis 11:45–60. https://doi.org/10.3233/JPD-201981
doi: 10.3233/JPD-201981
pubmed: 33074190
pmcid: 7990451
Bouali-Benazzouz R, Benazzouz A (2021) Covid-19 infection and Parkinsonism: is there a link? Mov Disord 36:1737–1743. https://doi.org/10.1002/mds.28680
doi: 10.1002/mds.28680
pubmed: 34080714
pmcid: 8242862
Burtscher J, Cappellano G, Omori A et al (2020) Mitochondria: in the cross fire of SARS-CoV-2 and immunity. iScience 23:101631. https://doi.org/10.1016/j.isci.2020.101631
Calculli A, Bocci T, Porcino M et al (2023) Parkinson disease following COVID‐19: report of six cases. Euro J Neurol 15732. https://doi.org/10.1111/ene.15732
Cavallieri F, Cury RG, Guimarães T et al (2023) Recent advances in the treatment of genetic forms of Parkinson’s disease: hype or hope? Cells 12:764. https://doi.org/10.3390/cells12050764
doi: 10.3390/cells12050764
pubmed: 36899899
pmcid: 10001341
Cavallieri F, Fioravanti V, Bove F et al (2022a) COVID-19 and parkinsonism: a critical appraisal. Biomolecules 12:970. https://doi.org/10.3390/biom12070970
doi: 10.3390/biom12070970
pubmed: 35883526
pmcid: 9313170
Cavallieri F, Fioravanti V, Toschi G et al (2022b) COVID-19 and Parkinson’s disease: a casual association or a possible second hit in neurodegeneration? J Neurol 269:59–61. https://doi.org/10.1007/s00415-021-10694-4
doi: 10.1007/s00415-021-10694-4
pubmed: 34216264
Cavallieri F, Sellner J, Zedde M, Moro E (2022c) Neurologic complications of coronavirus and other respiratory viral infections. In: Handbook of clinical neurology. Elsevier, Amsterdam, pp 331–358
Cevik M, Kuppalli K, Kindrachuk J, Peiris M (2020) Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ m3862. https://doi.org/10.1136/bmj.m3862
Chaná-Cuevas P, Salles-Gándara P, Rojas-Fernandez A et al (2020) The potential role of SARS-COV-2 in the pathogenesis of Parkinson’s disease. Front Neurol 11:1044. https://doi.org/10.3389/fneur.2020.01044
doi: 10.3389/fneur.2020.01044
pubmed: 33041985
pmcid: 7527541
Chen R, Wang K, Yu J et al (2021) The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains. Front Neurol 11:573095. https://doi.org/10.3389/fneur.2020.573095
doi: 10.3389/fneur.2020.573095
pubmed: 33551947
pmcid: 7855591
Chou SH-Y, Beghi E, Helbok R et al (2021) Global incidence of neurological manifestations among patients hospitalized with COVID-19—a report for the GCS-NeuroCOVID consortium and the energy consortium. JAMA Netw Open 4:e2112131. https://doi.org/10.1001/jamanetworkopen.2021.12131
doi: 10.1001/jamanetworkopen.2021.12131
pubmed: 33974053
pmcid: 8114143
Cohen ME, Eichel R, Steiner-Birmanns B et al (2020) A case of probable Parkinson’s disease after SARS-CoV-2 infection. Lancet Neurol 19:804–805. https://doi.org/10.1016/S1474-4422(20)30305-7
doi: 10.1016/S1474-4422(20)30305-7
pubmed: 32949534
pmcid: 7494295
Cosentino G, Todisco M, Hota N et al (2021) Neuropathological findings from COVID-19 patients with neurological symptoms argue against a direct brain invasion of SARS-CoV-2: a critical systematic review. Euro J Neurol 28:3856–3865. https://doi.org/10.1111/ene.15045
doi: 10.1111/ene.15045
Desai I, Manchanda R, Kumar N et al (2021) Neurological manifestations of coronavirus disease 2019: exploring past to understand present. Neurol Sci 42:773–785. https://doi.org/10.1007/s10072-020-04964-8
doi: 10.1007/s10072-020-04964-8
pubmed: 33428055
pmcid: 7798003
Dias V, Junn E, Mouradian MM (2013) The Role of Oxidative stress in Parkinson’s disease. J Parkinson’s Dis 3:461–491. https://doi.org/10.3233/JPD-130230
doi: 10.3233/JPD-130230
Dong Z, Cui H (2018) The autophagy-lysosomal pathways and their emerging roles in modulating proteostasis in tumors. Cells 8:4. https://doi.org/10.3390/cells8010004
doi: 10.3390/cells8010004
pubmed: 30577555
pmcid: 6356230
Emmi A, Rizzo S, Barzon L et al (2023) Detection of SARS-CoV-2 viral proteins and genomic sequences in human brainstem nuclei. NPJ Parkinsons Dis 9:25. https://doi.org/10.1038/s41531-023-00467-3
Fearon C, Mikulis DJ, Lang AE (2021) Parkinsonism as a sequela of SARS-CoV-2 infection: pure hypoxic injury or additional COVID-19-related response? Mov Disord 36:1483–1484. https://doi.org/10.1002/mds.28656
doi: 10.1002/mds.28656
pubmed: 34043246
pmcid: 8242400
Gain C, Song S, Angtuaco T et al (2023) The role of oxidative stress in the pathogenesis of infections with coronaviruses. Front Microbiol 13:1111930. https://doi.org/10.3389/fmicb.2022.1111930
doi: 10.3389/fmicb.2022.1111930
pubmed: 36713204
pmcid: 9880066
Ghosh S, Dellibovi-Ragheb TA, Kerviel A et al (2020) β-Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway. Cell 183:1520-1535.e14. https://doi.org/10.1016/j.cell.2020.10.039
doi: 10.1016/j.cell.2020.10.039
pubmed: 33157038
pmcid: 7590812
Gouda NA, Elkamhawy A, Cho J (2022) Emerging therapeutic strategies for Parkinson’s disease and future prospects: a 2021 Update. Biomedicines 10:371. https://doi.org/10.3390/biomedicines10020371
doi: 10.3390/biomedicines10020371
pubmed: 35203580
pmcid: 8962417
Hamming I, Timens W, Bulthuis M et al (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203:631–637. https://doi.org/10.1002/path.1570
doi: 10.1002/path.1570
pubmed: 15141377
pmcid: 7167720
Hawkes CH, Del Tredici K, Braak H (2007) Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 33:599–614. https://doi.org/10.1111/j.1365-2990.2007.00874.x
doi: 10.1111/j.1365-2990.2007.00874.x
pubmed: 17961138
pmcid: 7194308
Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052
doi: 10.1016/j.cell.2020.02.052
pubmed: 32142651
pmcid: 7102627
Iadecola C, Anrather J, Kamel H (2020) Effects of COVID-19 on the nervous system. Cell 183:16-27.e1. https://doi.org/10.1016/j.cell.2020.08.028
doi: 10.1016/j.cell.2020.08.028
pubmed: 32882182
pmcid: 7437501
Idrees D, Kumar V (2021) SARS-CoV-2 spike protein interactions with amyloidogenic proteins: potential clues to neurodegeneration. Biochem Biophys Res Commun 554:94–98. https://doi.org/10.1016/j.bbrc.2021.03.100
doi: 10.1016/j.bbrc.2021.03.100
pubmed: 33789211
pmcid: 7988450
Jackson CB, Farzan M, Chen B, Choe H (2022) Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol 23:3–20. https://doi.org/10.1038/s41580-021-00418-x
doi: 10.1038/s41580-021-00418-x
pubmed: 34611326
Käufer C, Schreiber CS, Hartke A-S et al (2022) Microgliosis and neuronal proteinopathy in brain persist beyond viral clearance in SARS-CoV-2 hamster model. eBioMedicine 79:103999. https://doi.org/10.1016/j.ebiom.2022.103999
Kempuraj D, Selvakumar GP, Ahmed ME et al (2020) COVID-19, Mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist 26:402–414. https://doi.org/10.1177/1073858420941476
doi: 10.1177/1073858420941476
pubmed: 32684080
Khomari F, Nabi-Afjadi M, Yarahmadi S et al (2021) Effects of cell proteostasis network on the survival of SARS-CoV-2. Biol Proced Online 23:8. https://doi.org/10.1186/s12575-021-00145-9
doi: 10.1186/s12575-021-00145-9
pubmed: 33618659
pmcid: 7899210
Korakas E, Ikonomidis I, Kousathana F et al (2020) Obesity and COVID-19: immune and metabolic derangement as a possible link to adverse clinical outcomes. Am J Physiol Endocrinol Metabol 319:E105–E109. https://doi.org/10.1152/ajpendo.00198.2020
doi: 10.1152/ajpendo.00198.2020
Kulkarni A, Preeti K, Tryphena KP et al (2023) Proteostasis in Parkinson’s disease: recent development and possible implication in diagnosis and therapeutics. Ageing Res Rev 84:101816. https://doi.org/10.1016/j.arr.2022.101816
doi: 10.1016/j.arr.2022.101816
pubmed: 36481490
Labbadia J, Morimoto RI (2015) The biology of proteostasis in aging and disease. Annu Rev Biochem 84:435–464. https://doi.org/10.1146/annurev-biochem-060614-033955
doi: 10.1146/annurev-biochem-060614-033955
pubmed: 25784053
pmcid: 4539002
Lan Y, He W, Wang G et al (2022) Potential Antiviral Strategy exploiting dependence of SARS-CoV-2 replication on lysosome-based pathway. Int J Mol Sci 23:6188. https://doi.org/10.3390/ijms23116188
doi: 10.3390/ijms23116188
pubmed: 35682877
pmcid: 9181800
Li C, Wang X, Li X et al (2019) Proteasome inhibition activates autophagy-lysosome pathway associated with TFEB dephosphorylation and nuclear translocation. Front Cell Dev Biol 7:170. https://doi.org/10.3389/fcell.2019.00170
doi: 10.3389/fcell.2019.00170
pubmed: 31508418
pmcid: 6713995
Lim K-L, Tan JMM (2007) Role of the ubiquitin proteasome system in Parkinson’s disease. BMC Biochem 8(Suppl1):S13. https://doi.org/10.1186/1471-2091-8-S1-S13
doi: 10.1186/1471-2091-8-S1-S13
pubmed: 18047737
pmcid: 2106364
Lyoo K-S, Kim HM, Lee B et al (2022) Direct neuronal infection of SARS-CoV-2 reveals cellular and molecular pathology of chemosensory impairment of COVID-19 patients. Emerg Microbes Infect 11:407–412. https://doi.org/10.1080/22221751.2021.2024095
doi: 10.1080/22221751.2021.2024095
Makhoul K, Jankovic J (2021) Parkinson’s disease after COVID-19. J Neurol Sci 422:117331. https://doi.org/10.1016/j.jns.2021.117331
doi: 10.1016/j.jns.2021.117331
pubmed: 33540185
pmcid: 9755718
Mandrioli J, D’Amico R, Zucchi E et al (2018) Rapamycin treatment for amyotrophic lateral sclerosis: protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial). Medicine 97:e11119. https://doi.org/10.1097/MD.0000000000011119
doi: 10.1097/MD.0000000000011119
pubmed: 29901635
pmcid: 6024184
McLelland G-L, Soubannier V, Chen CX et al (2014) Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control. EMBO J 33:282–295. https://doi.org/10.1002/embj.201385902
doi: 10.1002/embj.201385902
pubmed: 24446486
pmcid: 3989637
Mehta P, McAuley DF, Brown M et al (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395:1033–1034. https://doi.org/10.1016/S0140-6736(20)30628-0
doi: 10.1016/S0140-6736(20)30628-0
pubmed: 32192578
pmcid: 7270045
Méndez-Guerrero A, Laespada-García MI, Gómez-Grande A et al (2020) Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Neurology 95:e2109–e2118. https://doi.org/10.1212/WNL.0000000000010282
doi: 10.1212/WNL.0000000000010282
pubmed: 32641525
Merello M, Bhatia KP, Obeso JA (2021) SARS-CoV-2 and the risk of Parkinson’s disease: facts and fantasy. Lancet Neurol 20:94–95. https://doi.org/10.1016/S1474-4422(20)30442-7
doi: 10.1016/S1474-4422(20)30442-7
pubmed: 33253627
Moro E, Priori A, Beghi E et al (2020) The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection. Eur J Neurol 27:1727–1737. https://doi.org/10.1111/ene.14407
doi: 10.1111/ene.14407
pubmed: 32558002
Narendra DP, Youle RJ (2011) Targeting mitochondrial dysfunction: role for PINK1 and Parkin in mitochondrial quality control. Antioxid Redox Signal 14:1929–1938. https://doi.org/10.1089/ars.2010.3799
doi: 10.1089/ars.2010.3799
pubmed: 21194381
pmcid: 3078490
Ndayisaba A, Wenning GK (2020) Inhibition of the mammalian target or rapamycin (mTOR): a potential therapeutic strategy for multiple system atrophy. Clin Auton Res 30:7–8. https://doi.org/10.1007/s10286-019-00662-4
doi: 10.1007/s10286-019-00662-4
pubmed: 31919620
Nedelsky NB, Todd PK, Taylor JP (2008) Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. Biochim Biophys Acta 1782:691–699. https://doi.org/10.1016/j.bbadis.2008.10.002
doi: 10.1016/j.bbadis.2008.10.002
pubmed: 18930136
pmcid: 2621359
Palacios Cruz M, Santos E, Velázquez Cervantes MA, León Juárez M (2021) COVID-19, a worldwide public health emergency. Revista Clínica Española (English Edition) 221:55–61. https://doi.org/10.1016/j.rceng.2020.03.001
doi: 10.1016/j.rceng.2020.03.001
Pavli A, Theodoridou M, Maltezou HC (2021) Post-COVID syndrome: incidence, clinical spectrum, and challenges for primary healthcare professionals. Arch Med Res 52:575–581. https://doi.org/10.1016/j.arcmed.2021.03.010
doi: 10.1016/j.arcmed.2021.03.010
pubmed: 33962805
pmcid: 8093949
Philippens IHCHM, Böszörményi KP, Wubben JAM et al (2022) Brain inflammation and intracellular α-Synuclein aggregates in macaques after SARS-CoV-2 infection. Viruses 14:776. https://doi.org/10.3390/v14040776
doi: 10.3390/v14040776
pubmed: 35458506
pmcid: 9025893
Pierce JD, Shen Q, Cintron SA, Hiebert JB (2022) Post-COVID-19 syndrome. Nurs Res 71:164–174. https://doi.org/10.1097/NNR.0000000000000565
doi: 10.1097/NNR.0000000000000565
pubmed: 34653099
Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047. https://doi.org/10.1126/science.276.5321.2045
doi: 10.1126/science.276.5321.2045
pubmed: 9197268
Preiser J-C (2012) Oxidative stress. JPEN J Parenter Enteral Nutr 36:147–154. https://doi.org/10.1177/0148607111434963
doi: 10.1177/0148607111434963
pubmed: 22301329
Raaben M, Posthuma CC, Verheije MH et al (2010) The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle. J Virol 84:7869–7879. https://doi.org/10.1128/JVI.00485-10
doi: 10.1128/JVI.00485-10
pubmed: 20484504
pmcid: 2897594
Ramaiah MJ (2020) MTOR inhibition and p53 activation, microRNAs: the possible therapy against pandemic COVID-19. Gene Rep 20:100765. https://doi.org/10.1016/j.genrep.2020.100765
doi: 10.1016/j.genrep.2020.100765
pubmed: 32835132
pmcid: 7324924
Raveendran AV, Jayadevan R, Sashidharan S (2021) Long COVID: an overview. Diabetes Metab Syndr 15:869–875. https://doi.org/10.1016/j.dsx.2021.04.007
doi: 10.1016/j.dsx.2021.04.007
pubmed: 33892403
pmcid: 8056514
Reza-Zaldívar EE, Hernández-Sapiéns MA, Minjarez B et al (2021) Infection mechanism of SARS-COV-2 and its implication on the nervous system. Front Immunol 11:621735. https://doi.org/10.3389/fimmu.2020.621735
doi: 10.3389/fimmu.2020.621735
pubmed: 33584720
pmcid: 7878381
Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E et al (2020) Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. Neurology 95:e1060–e1070. https://doi.org/10.1212/WNL.0000000000009937
doi: 10.1212/WNL.0000000000009937
pubmed: 32482845
pmcid: 7668545
Sala G, Marinig D, Arosio A, Ferrarese C (2016) Role of chaperone-mediated autophagy dysfunctions in the pathogenesis of Parkinson’s disease. Front Mol Neurosci 9:157. https://doi.org/10.3389/fnmol.2016.00157
doi: 10.3389/fnmol.2016.00157
pubmed: 28066181
pmcid: 5179559
Seirafi M, Kozlov G, Gehring K (2015) Parkin structure and function. FEBS J 282:2076–2088. https://doi.org/10.1111/febs.13249
doi: 10.1111/febs.13249
pubmed: 25712550
pmcid: 4672691
Semerdzhiev SA, Fakhree MAA, Segers-Nolten I et al (2022) Interactions between SARS-CoV-2 N-Protein and α-Synuclein accelerate amyloid formation. ACS Chem Neurosci 13:143–150. https://doi.org/10.1021/acschemneuro.1c00666
doi: 10.1021/acschemneuro.1c00666
pubmed: 34860005
Seyoum Tola F (2023) The role of ubiquitin-proteasome system in the pathogenesis of severe acute respiratory syndrome coronavirus-2 disease. Int J Inflam 2023:6698069. https://doi.org/10.1155/2023/6698069
Shang C, Liu Z, Zhu Y et al (2021) SARS-CoV-2 causes mitochondrial dysfunction and mitophagy impairment. Front Microbiol 12:780768. https://doi.org/10.3389/fmicb.2021.780768
doi: 10.3389/fmicb.2021.780768
pubmed: 35069483
Shin W-J, Ha DP, Machida K, Lee AS (2022) The stress-inducible ER chaperone GRP78/BiP is upregulated during SARS-CoV-2 infection and acts as a pro-viral protein. Nat Commun 13:6551. https://doi.org/10.1038/s41467-022-34065-3
doi: 10.1038/s41467-022-34065-3
pubmed: 36376289
pmcid: 9663498
Sinha S, Mittal S, Roy R (2021) Parkinson’s disease and the COVID-19 pandemic: a review article on the association between SARS-CoV-2 and α-Synucleinopathy. JMD 14:184–192. https://doi.org/10.14802/jmd.21046
Sodagar A, Javed R, Tahir H et al (2022) Pathological features and neuroinflammatory mechanisms of SARS-CoV-2 in the brain and potential therapeutic approaches. Biomolecules 12:971. https://doi.org/10.3390/biom12070971
doi: 10.3390/biom12070971
pubmed: 35883527
pmcid: 9313047
Song E, Zhang C, Israelow B et al (2021) Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med 218:e20202135. https://doi.org/10.1084/jem.20202135
doi: 10.1084/jem.20202135
pubmed: 33433624
pmcid: 7808299
Soung AL, Vanderheiden A, Nordvig AS et al (2022) COVID-19 induces CNS cytokine expression and loss of hippocampal neurogenesis. Brain 145:4193–4201. https://doi.org/10.1093/brain/awac270
doi: 10.1093/brain/awac270
pubmed: 36004663
pmcid: 9452175
Stroylova Y, Konstantinova A, Stroylov V et al (2023) Does the SARS-CoV-2 spike receptor-binding domain hamper the amyloid transformation of Alpha-Synuclein after all? Biomedicines 11:498. https://doi.org/10.3390/biomedicines11020498
doi: 10.3390/biomedicines11020498
pubmed: 36831034
pmcid: 9953139
Sulzer D, Antonini A, Leta V et al (2020) COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside. NPJ Parkinsons Dis 6:18. https://doi.org/10.1038/s41531-020-00123-0
Sulzer D, Edwards RH (2019) The physiological role of α-synuclein and its relationship to Parkinson’s Disease. J Neurochem 150:475–486. https://doi.org/10.1111/jnc.14810
doi: 10.1111/jnc.14810
pubmed: 31269263
pmcid: 6707892
Swain O, Romano SK, Miryala R et al (2021) SARS-CoV-2 neuronal invasion and complications: potential mechanisms and therapeutic approaches. J Neurosci 41:5338–5349. https://doi.org/10.1523/JNEUROSCI.3188-20.2021
doi: 10.1523/JNEUROSCI.3188-20.2021
pubmed: 34162747
pmcid: 8221594
Terrazzano G, Rubino V, Palatucci AT et al (2020) An open question: is it rational to inhibit the mTor-dependent pathway as COVID-19 therapy? Front Pharmacol 11:856. https://doi.org/10.3389/fphar.2020.00856
doi: 10.3389/fphar.2020.00856
pubmed: 32574238
pmcid: 7273850
Tiwari SK, Wang S, Smith D et al (2021) Revealing tissue-specific SARS-CoV-2 infection and host responses using human stem cell-derived lung and cerebral organoids. Stem Cell Rep 16:437–445. https://doi.org/10.1016/j.stemcr.2021.02.005
doi: 10.1016/j.stemcr.2021.02.005
Tofaris GK, Razzaq A, Ghetti B et al (2003) Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 278:44405–44411. https://doi.org/10.1074/jbc.M308041200
doi: 10.1074/jbc.M308041200
pubmed: 12923179
Trinh D, Israwi AR, Arathoon LR et al (2021) The multi-faceted role of mitochondria in the pathology of Parkinson’s disease. J Neurochem 156:715–752. https://doi.org/10.1111/jnc.15154
doi: 10.1111/jnc.15154
pubmed: 33616931
Vollbracht C, Kraft K (2022) Oxidative stress and hyper-inflammation as major drivers of severe COVID-19 and long COVID: implications for the benefit of high-dose intravenous Vitamin C. Front Pharmacol 13:899198. https://doi.org/10.3389/fphar.2022.899198
doi: 10.3389/fphar.2022.899198
pubmed: 35571085
pmcid: 9100929
Weissmann G, Dukor P (1970) The role of lysosomes in immune responses. In: Advances in immunology. Elsevier, Amsterdam, pp 283–331
Wong YC, Krainc D (2017) α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med 23:1–13. https://doi.org/10.1038/nm.4269
doi: 10.1038/nm.4269
pubmed: 28170377
pmcid: 8480197
Wu Z, Zhang X, Huang Z, Ma K (2022) SARS-CoV-2 Proteins interact with Alpha Synuclein and induce Lewy body-like pathology in vitro. Int J Mol Sci 23:3394. https://doi.org/10.3390/ijms23063394
doi: 10.3390/ijms23063394
pubmed: 35328814
pmcid: 8949667
Xiong H, Wang D, Chen L et al (2009) Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest 119:650–660. https://doi.org/10.1172/JCI37617
doi: 10.1172/JCI37617
pubmed: 19229105
pmcid: 2648688
Yahya V, Di Fonzo A, Monfrini E (2023) Genetic evidence for endolysosomal dysfunction in Parkinson’s disease: a critical overview. IJMS 24:6338. https://doi.org/10.3390/ijms24076338
doi: 10.3390/ijms24076338
pubmed: 37047309
pmcid: 10094484
Yang L, Han Y, Nilsson-Payant BE et al (2020) A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell 27:125-136.e7. https://doi.org/10.1016/j.stem.2020.06.015
doi: 10.1016/j.stem.2020.06.015
pubmed: 32579880
pmcid: 7303620
Zabetakis I, Lordan R, Norton C, Tsoupras A (2020) COVID-19: The inflammation link and the role of nutrition in potential mitigation. Nutrients 12:1466. https://doi.org/10.3390/nu12051466
doi: 10.3390/nu12051466
pubmed: 32438620
pmcid: 7284818
Zhang Y, Sun H, Pei R et al (2021) The SARS-CoV-2 protein ORF3a inhibits fusion of autophagosomes with lysosomes. Cell Discov 7:31. https://doi.org/10.1038/s41421-021-00268-z
doi: 10.1038/s41421-021-00268-z
pubmed: 33947832
pmcid: 8096138
Zubair AS, McAlpine LS, Gardin T et al (2020) Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a Review. JAMA Neurol 77:1018. https://doi.org/10.1001/jamaneurol.2020.2065
doi: 10.1001/jamaneurol.2020.2065
pubmed: 32469387
pmcid: 7484225